title: The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy.
abstract: Decay-accelerating factor (DAF, CD55) is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. Here DAF seems to exert different functions beyond its immunological role such as e.g. promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathways and specific seven-span transmembrane receptors (CD97) binding. Therefore, DAF has already become a target for therapy. In this paper we review the role of DAF in human malignancies as described in different basic, diagnostic and experimental therapeutic studies.
authors.affiliation: Department of Haematology-Oncology, University of Muenster, Germany.
authors.forename: Jan-Henrik
authors.initials: JH
authors.lastname: Mikesch
authors.forename: Kathrin
authors.initials: K
authors.lastname: Schier
authors.forename: Antje
authors.initials: A
authors.lastname: Roetger
authors.forename: Ronald
authors.initials: R
authors.lastname: Simon
authors.forename: Horst
authors.initials: H
authors.lastname: Buerger
authors.forename: Burkhard
authors.initials: B
authors.lastname: Brandt
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D018958:CD55 Antigens / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D008562:Membrane Glycoproteins / Q000378:metabolism; D009369:Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D019000:Phosphotyrosine / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled; D015398:Signal Transduction
chemical_list: C095004:ADGRE5 protein, human; D015703:Antigens, CD; D018958:CD55 Antigens; D008024:Ligands; D008562:Membrane Glycoproteins; D043562:Receptors, G-Protein-Coupled; D019000:Phosphotyrosine